Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.40 |
| ▸ | CDC25B | P30305 | 5/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.40 |
| ▸ | CDC25A | P30304 | 3/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520655 | 0.91 | SLC5A2 (0.43) | SLC5A2PTPN1CDC25BBCHETACR2 | |
| SCHEMBL12509830 | 0.90 | SLC5A2 (0.42) | SLC5A2PTPN1 | |
| SCHEMBL12425898 | 0.88 | SLC5A2 (0.45) | SLC5A2PTPN1BCHETACR2SSTR4 | |
| SCHEMBL5526843 | 0.87 | PTPN1 (0.43) | SLC5A2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL12425892 | 0.85 | SLC5A2 (0.47) | SLC5A2PTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL5531075 | 0.85 | SLC5A2 (0.43) | SLC5A2PTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL5526226 | 0.85 | SLC5A2 (0.46) | SLC5A2PTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL12425939 | 0.85 | SLC5A2 (0.48) | SLC5A2PTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL12425888 | 0.84 | SLC5A2 (0.47) | SLC5A2PTPN1PTPN2PTPN11TACR2 | |
| SCHEMBL5516727 | 0.83 | SLC5A2 (0.45) | SLC5A2PTPN1CDC25BPTPN2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7772407-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885PTPN1 224/4885CDC25B 4395/4885 |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885PTPN1 224/4885CDC25B 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.